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Abstract
Rationale: Noncommunicable respiratory diseases and exposure to
air pollution are thought to be important contributors to morbidity
and mortality in sub-Saharan African adults.
Objectives:We set out to explore the prevalence and determinants
of noncommunicable respiratory disease among adults living in
Chikhwawa District, Malawi.
Methods:We performed a cross-sectional study among adults in
communities participating in a randomized controlled trial of a
cleaner-burning biomass-fueled cookstove intervention (CAPS
[Cooking and Pneumonia Study]) in rural Malawi. We assessed
chronic respiratory symptoms, spirometric abnormalities, and
personal exposure to air pollution (particulate matter,2.5 mm
in aerodynamic diameter [PM2.5] and carbon monoxide [CO]).
Weighted prevalence estimates were calculated; multivariable and
intention-to-treat analyses were done.
Measurements and Main Results: One thousand four hundred
eighty-one participants (mean [SD] age, 43.8 [17.8] yr; 57% female)
were recruited. The prevalence of chronic respiratory symptoms,
spirometric obstruction, and restriction were 13.6% (95% confidence
interval [CI], 11.9–15.4), 8.7% (95% CI, 7.0–10.7), and 34.8% (95%
CI, 31.7–38.0), respectively. Median 48-hour personal PM2.5 and CO
exposures were 71.0 mg/m3 (interquartile range [IQR], 44.6–119.2)
and 1.23 ppm (IQR, 0.79–1.93), respectively. Chronic respiratory
symptoms were associated with current/ex-smoking (odds ratio
[OR], 1.59; 95% CI, 1.05–2.39), previous tuberculosis (OR, 2.50; 95%
CI, 1.04–15.58), and CO exposure (OR, 1.46; 95% CI, 1.04–2.05).
Exposure to PM2.5 was not associated with any demographic,
clinical, or spirometric characteristics. There was no effect of the
CAPS intervention on any of the secondary trial outcomes.
Conclusions:The burden of chronic respiratory symptoms, abnormal
spirometry, and air pollution exposures in adults in rural Malawi is of
considerable potential public health importance. We found little
evidence that air pollution exposures were associated with chronic
respiratory symptoms or spirometric abnormalities and no evidence
that the CAPS intervention had effects on the secondary trial outcomes.
More effective prevention and control strategies for noncommunicable
respiratory disease in sub-Saharan Africa are needed.
Clinical trial registered with www.isrctn.com (ISRCTN 59448623).
Keywords: household air pollution; Malawi; chronic obstructive
pulmonary disease; Cooking and Pneumonia Study; cookstove
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Highly polluting fuels, including animal
dung, crop residues, wood, charcoal, and
kerosene, are used by almost half the world’s
population to provide energy for cooking,
heating, and lighting (1–3). These fuels are
typically burned in and around the home
environment in inefficient ways (e.g., open
fires), which leads to high levels of air
pollution in and immediately outside of
homes. The World Health Organization
(WHO) has estimated that exposure to
household air pollution leads to .4 million
deaths each year (3). The latest Global
Burden of Disease Study estimates this
number is closer to 2.5 million, but even
these lower estimates represent a substantial
burden of morbidity and mortality that falls
particularly heavily on the world’s poor (4).
Household air pollution has been considered
to increase the risk of pneumonia in children
and of chronic obstructive pulmonary
disease (COPD) and cardiovascular disease
in adults (1–3).
In 2017, we published the findings of
a cluster-randomized controlled trial of
introducing a cleaner-burning biomass-
fueled cookstove to prevent pneumonia in
children ,5 years of age in rural Malawi
(CAPS [Cooking and Pneumonia Study])
(5). CAPS is one of a small number of trials
done to date to evaluate the effects of
reducing biomass smoke exposure on
health outcomes and is the largest trial of a
cookstove intervention on health outcomes
conducted anywhere in the world (n =
10,750 children from 8,626 households
across 150 clusters). The major finding of
this trial was that there was no difference
between the intervention and control
groups among children in pneumonia
incidence defined using the criteria of the
Integrated Management of Childhood
Illness program. This unexpected finding
has cast some doubt on the assumptions
made by the Global Alliance for Clean
Cookstoves that cleaner cookstoves and
fuels save lives (6–11).
Herein we report the findings of a
cross-sectional study of the prevalence
and determinants of noncommunicable
respiratory disease among adults living in
communities that participated in CAPS,
which addresses the prespecified secondary
trial objective of determining prevalence and
determinants of obstructive lung disease in
adults in rural Malawi (5). In this setting,
use of highly polluting fuels for day-to-day
household energy requirements is the
norm, and therefore a high burden of
COPD associated with household air
pollution was expected.
Methods
Study Design
We performed a cross-sectional study of
the prevalence and determinants of
noncommunicable respiratory disease among
adults living in Chikhwawa District, Malawi.
Setting
Chikhwawa is z50 km from the nearest
city, Blantyre, on the southern Shire River
Valley, and it consists primarily of
subsistence farmers living in rural village
communities. The Malawi College of
Medicine Research Ethics Committee
(Ethics Committee reference no. P.11/12/1308)
and the Liverpool School of Tropical
Medicine Research Ethics Committee
(Ethics Committee reference no. 12.40)
approved the CAPS trial protocol that
includes this work, a summary of which
was published by The Lancet (12).
Participants
Following community engagement events
that included village leaders and other
community representatives, a list of all the
adults living in each of the 50 villages
participating in CAPS in Chikhwawa was
obtained from local community health
workers known as Health Surveillance
Assistants. These lists were collated and
used by an independent statistician at the
BOLD (Burden of Obstructive Lung Disease)
center in London to obtain a population-
representative sample of adults .18 years of
age with stratification by age and sex. All
potential participants sampled in this way
were then individually invited to participate
with written informed consent (or witnesses
thumbprint for those unable to read and
write) obtained from those who agreed.
People who were acutely unwell, not
Author Contributions: Design: K.M., P.B., and J.B. Acquisition of data: R.N., K.M., P.B., and J.B. Analysis of data: R.N., M.L., G.F., and S.J.R. Interpretation of
data: R.N., M.L., G.F., S.J.R., J.M., P.B., J.B., and K.M. Writing the manuscript, approval of the version to be published, and agreement to be accountable for
all aspects of the work: all authors.
Correspondence and requests for reprints should be addressed to Kevin Mortimer, Ph.D., Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3
5QA, UK. E-mail: kevin.mortimer@lstmed.ac.uk.
At a Glance Commentary
Scientific Knowledge on the
Subject: Noncommunicable
respiratory diseases and exposure to air
pollution are thought to be important
causes of morbidity and mortality in
sub-Saharan African adults. Recent
BOLD (Burden of Obstructive Lung
Disease) studies found a high burden
of spirometric restriction but little
spirometric obstruction in several sub-
Saharan African countries and no
association between spirometric
obstruction and use of dirty-burning
fuels. It is not known whether an
association between spirometric
obstruction and solid fuel use would
be seen if personal exposure to air
pollution were measured in addition
to self-reported exposure. CAPS
(Cooking and Pneumonia Study)—a
trial of cleaner burning biomass-fueled
cookstoves on pneumonia in children
,5 years of age in rural Malawi—
offered the opportunity to explore this
and other secondary trial outcomes in
adults.
What This Study Adds to the
Field: In adults living in Chikhwawa,
rural Malawi: 13.6% of participants had
chronic respiratory symptoms (mainly
cough); .40% had abnormal
spirometry (mainly spirometric
restriction); day-to-day air pollution
exposures were approximately three
times the World Health Organization
upper safety limit; air pollution
exposures were not associated with
demographic, clinical, or spirometric
characteristics; and there was no
association between CAPS trial arm
and any of the secondary trial
outcomes.
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permanent residents, or pregnant were
excluded.
Procedures
Fieldworkers who had undergone study-
specific training and met the required
quality standards did home visits according
to standardized operating procedures.
With the exception of the air pollution
monitoring procedures that are not part of
the BOLD study protocol, all procedures
were conducted in accordance with the
BOLD study protocol, which has been
described previously (13). Minimal
demographic information was collected
from participants who declined to
participate in the full study. Fieldworkers
administered BOLD study questionnaires
in the local language, Chichewa. Height and
weight were measured using a portable
stadiometer and scales. All eligible
participants were asked to do before and
after bronchodilator spirometry, which
BOLD center–certified fieldworkers
performed to European Respiratory
Society/American Thoracic Society
guidelines using the ndd EasyOne
spirometer (ndd Medical Technologies)
(14). Up to three repeat visits were arranged
to achieve the required spirometry quality
standards. Spirometry data were sent
electronically to the BOLD center for
quality control.
Personal exposures to particulate matter
,2.5 mm in aerodynamic diameter (PM2.5)
and carbon monoxide (CO) were measured
continuously for 48 hours using the indoor
air pollution (IAP) 5000 series monitor
(Aprovecho Research Center). The IAP 5000
sampled air from the breathing zone using a
short tube and logged continuous PM2.5 and
CO using a light-scattering photometer
and an electrochemical cell CO sensor,
respectively. All monitors were calibrated at
the Aprovecho Research Center prior to use
in the study. Monitors were worn in small
backpacks apart from during sleep, when
they were kept beside the sleeping mat or
bed.
Variables
Clinical outcomes were presence or absence
of specific symptoms as assessed by a
questionnaire. The questions (outcomes)
asked were as follows: Do you usually have a
cough when you don’t have a cold (cough
outcome)? Do you usually bring up phlegm
from your chest (phlegm outcome)? Have
you had wheezing/whistling in your chest at
any point in the last 12 months, in the
absence of a cold (wheeze outcome)? Do
you have shortness of breath when
hurrying on the level or walking up a slight
hill (dyspnea outcome)? And have your
breathing problems interfered with your
daily activities (functional limitation
outcome)? A composite variable for any
symptoms was created by defining as
positive if an individual reported any of the
above symptoms (any symptoms outcome).
Continuous FEV1 and FVC spirometry
values were used in the primary analysis.
Spirometric obstruction and restriction were
defined according to the NHANES III white
reference range lower limits of normal (15).
Exposures of interest included personal
exposure to PM2.5 or CO as measured by
the personal monitoring device, and two
exposures assessed by questionnaire:
smoking status and previous episode of
tuberculosis (TB). A questionnaire-assessed
variable asking for any biomass exposure
was considered, but as most (.99%)
indicated yes, it was not included in any
modeling.
Raw PM2.5 and CO exposures were
corrected for background levels using
Age and gender stratified random sampling
N = 3,000
Ineligible for inclusion or unable to locate
n = 1,519
Unable to physically cooperate
n = 258
Acceptable
spirometry
N = 886
Unacceptable
spirometry
N = 64
Contra-indication (medically unfit) = 193
Heart conditions = 38
Pregnancy = 24
Recent eye/chest surgery = 13
Active TB = 9
Pulse > 120 bpm = 3
Other = 106
Refused to do spirometry = 69
Unable to understand instructions = 11
Eligible for inclusion and consented
to participate
N = 1,481
Completed data collection and attempted
spirometry
N = 1208
Chikhwawa, rural study target population
N = 62,207
Figure 1. Participant recruitment flow diagram. TB = tuberculosis.
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calibration values for each monitoring
period. In cases where calibration data
were missing or corrupted (,5%),
aggregated mean calibration values were
used. Observations where ,2,000 minutes
of time were recorded were excluded, as
were monitoring periods affected by device
malfunction. Both PM2.5 and CO were
log10 transformed for presentation and
inclusion in models due to large positive
skew.
Potential confounders/effect modifiers
included were body mass index (BMI)
and/or height (cm) and weight (kg)
variables, as well as age, years of education,
and sex.
Study Size
We initially invited 2,000 people to
participate but increased this to 3,000
to achieve the required sample size.
Participants were stratified into two age
groups: 18–39 years and >40 years. We
estimated that, after allowing for unequal
age and sex distributions, refusals, and
inability to provide spirometry
measurements of acceptable quality, a
sample of just 300 participants in any
one sex/age stratum (1,200 total) would
provide an estimate of chronic airflow
limitation prevalence in this stratum with
a precision (95% confidence interval [CI])
of 63.3% to 65.0% assuming a prevalence
of 10–25%.
Statistical Analyses
Univariate analysis was completed using
descriptive statistics to explore the
characteristics of the study population.
Descriptive analysis is presented for
clarity using categorical versions of BMI
(underweight, normal, overweight, or obese)
and categorical versions of age; however,
age, weight, and height were entered into
models as continuous variables. Participants
who completed the study in full or in part
were assessed for selection bias using the x2
and Student’s t tests. Multivariable logistic
regression was used to estimate the strength
of the association between measured
exposure variables and dichotomous
clinical outcomes, adjusting for potential
confounders. All models were adjusted for
age, sex, weight, and height. Linear
multivariable regression was used to
estimate the association between exposures
and continuous lung function values
(FEV1, FVC, and FEV1/FVC). Secondary
exploratory trial efficacy analyses were by
intention to treat. Statistical significance
was nominally set at a = 0.05. Stata version
14.2 and R version 3.4 statistical software
was used for data analysis (Stata statistical
software: R.14; StataCorp, LLC).
Role of the Funding Source
The funders had no role in the study design,
data collection, analysis, interpretation, or
writing of the report. The corresponding
author had full access to all the study
data and had final responsibility for the
decision to submit for publication.
Results
Between August 2014 and July 2015, we
attempted to contact the 3,000 adults
Table 1. Demographic and Clinical Characteristics (N = 1,481)
Characteristic Level n (%) or Mean (SD)
Age group, yr ,39 686 (46.32)
40–49 259 (17.49)
50–59 216 (14.58)
60–69 160 (10.80)
.70 160 (10.80)
Sex Male 637 (43.01)
Female 844 (56.99)
Education None 485 (32.79)
Primary 758 (51.25)
Middle 205 (13.86)
High school or college 31 (2.10)
Missing 2 (0.0)
Years of education, mean (SD) 4.20 (4.09)
Years of education if any, mean (SD) 6.31 (3.44)
Smoking Never smoker 1,152 (77.8)
Current or ever smoker 328 (22.2)
Pack-years of smoking 0 1,152 (77.8)
Up to 10 pack-years 263 (17.8)
.10 pack-years 63 (4.3)
Missing 3 (0.0)
BMI group, kg/m2 Underweight (BMI, ,18.5) 188 (14.4)
Normal (BMI, 18.5–25) 945 (72.5)
Overweight (BMI, 25–30) 130 (10.0)
Obese (BMI, .30) 40 (3.1)
Missing 178 (12.0)
Previous TB No 1,434 (92.3)
Yes 47 (3.2)
Symptoms Cough (Do you usually cough when you
don’t have a cold?)
165 (11.1)
Sputum (Do you usually bring up phlegm
from your chest?)
38 (2.6)
Wheeze (Have you had
wheezing/whistling in your chest at any
point in past 12 months in the absence
of a cold?)
23 (1.6)
MRC dyspnea II (Do you have shortness
of breath when hurrying on the level or
walking up a slight hill?)
23 (1.6)
Any respiratory symptoms (Any of cough,
sputum, wheeze without cold,
exertional breathlessness as above?)
201 (13.6)
Functional limitation (Have breathing
problems interfered with your usual
daily activities?)
43 (2.9)
Definition of abbreviations: BMI = body mass index; MRC =Medical Research Council; TB = tuberculosis.
Data are n (%) unless otherwise indicated.
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sampled to invite them to participate, of
whom 1,481 (49.4%) consented and
completed BOLD study questionnaires.
Of these, 950 (64.6%) went on to do
spirometry; the remaining 520 (35.3%)
were unable to do spirometry because they
could not physically cooperate with the
procedure (n = 258; 48.9%), had a
fieldworker-determined contraindication
(n = 193; 37%), or refused (n = 69; 13.3%).
Of the 1,481 participants, 1,144 (77.2%)
underwent personal air pollution exposure
monitoring. There were 424 (28.6%)
participants from CAPS intervention or
control households (Figure 1).
The mean age (SD) of participants was
43.8 (17.8) years and 57% were female
(Table 1). Just more than half of the
participants had been educated only to
primary school level, with a third having
had no formal school education. The use
of biomass fuels for cooking was almost
universal (99.8%).
One or more chronic respiratory
symptom was reported by 201 (13.6%; 95%
CI, 11.9–15.4) participants (Table 1 and
Figure 2). Respiratory symptoms were more
commonly reported with increasing age.
Regular cough was reported by 11.1% (95%
CI, 9.6–12.8) while 2.6% (95% CI, 1.9–3.5)
reported usually coughing up phlegm.
Breathlessness and wheeze were less
commonly reported: 1.6% (95% CI, 1.0–2.3)
and 1.6% (95% CI, 1.0–2.3), respectively.
Respiratory symptoms that limited
functional ability were reported by 2.9%
(95% CI, 2.2–3.9). A previous diagnosis of
TB was reported by 3.2% (95% CI, 2.4–4.2),
which was more common with increasing
age. Current or former smoking was
reported by 22.1% (95% CI, 20.1–24.3),
although only 4.3% had a .10 pack-year
history. Many participants (14.4%) had a
low BMI.
Of the 950 participants who did
spirometry, 886 (93.2%) achieved BOLD
study quality standards and were included
in the analyses. Factors associated with
declining or not completing spirometry to
European Respiratory Society/American
Thoracic Society standards were older
mean age (48 vs. 39 yr; P, 0.001), being
female (65% vs. 51%; P, 0.001), lower
mean years of education (2 vs. 5 yr; P,
0.001), and lower mean BMI (20.7 vs. 21.3;
P, 0.001). As shown in Table E1 in the
online supplement, participants who
completed spirometry were less likely to
have cough, wheeze, and dyspnea
compared with those who did not
complete spirometry and were slightly
more likely to have phlegm and functional
limitation, although none of these
differences was statistically significant.
Spirometric obstruction and restriction
were present in 8.7% (95% CI, 7.0–10.7)
and 34.8% (95% CI, 31.7–38.0) of the 886
participants who met the required quality
standards, respectively.
Of the 1,144 participants (mean age
[SD], 43.9 [17.9] yr; 57% female) who
underwent personal exposure monitoring,
1,117 (97.6%) had valid exposure
monitoring records. The 48-hour median
personal PM2.5 and CO exposures were
71.0 mg/m3 (interquartile range [IQR],
44.6–119.2) and 1.23 ppm (IQR, 0.79–1.93),
respectively. There was weak correlation
between these two air pollution exposure
measures (Figure 3).
In logistic multivariable analysis,
smoking (odds ratio [OR], 1.56; 95% CI,
1.01–2.41) and previous TB (OR, 2.81;
95% CI, 1.19–6.08) were associated with
cough (Table 2 and Table E1). In
continuous multivariable analysis, both
FEV1 and FVC had a negative association
with increasing age and were higher for
men compared with women (Table 3).
Smoking (coefficient estimate, 20.09; 95%
CI, 20.16 to 20.01) and previous TB
(coefficient estimate, 20.46; 95% CI,
20.64 to 20.28) were associated with
FEV1, and previous TB was associated
with FVC (coefficient estimate, 20.35;
95% CI, 20.56 to 20.15). There was no
association between personal exposure to
PM2.5 and any of the demographic and
clinical characteristics or spirometric
20
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Figure 2. Age-stratified prevalence of respiratory symptoms.
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indices (Tables 4 and 5). The only
statistically significant association was
between exposure to CO and reporting
“any chronic respiratory symptoms”
(OR, 1.46; 95% CI, 1.04–2.05). There were
no statistically significant associations
between personal exposure to CO and
any other demographic and clinical
characteristics or to any spirometric
indices. There were 424 (227 intervention;
197 control) participants in the CAPS
intention-to-treat population; however,
not all of them had complete spirometry
(133 without) or exposure measures (87
without). There were no differences in
respiratory symptoms, spirometric
indices, or exposure to CO or PM2.5
between the intervention and control
groups (Table 6).
Discussion
The main findings of this cross-sectional
study of the burden and determinants of
noncommunicable respiratory disease in
adults living in Chikhwawa, rural Malawi,
were that: 13.6% of participants had
chronic respiratory symptoms (mainly
cough); .40% had abnormal spirometry
(mainly spirometric restriction); day-to-
day air pollution exposures were
approximately three times the WHO
upper safety limit; and there was no
association between CAPS trial arm and
any of the secondary trial outcomes in the
subset of adults included both in this study
and the trial.
The finding of a low prevalence of
spirometric obstruction in this setting—
where highly polluting fuels are almost
universally used for household energy
needs and where exposure to household
air pollution is high—is surprising given
that household air pollution–associated
COPD has been suggested to be a major
global health problem and as such would
be expected to be highly prevalent in our
study setting (16–19). This finding is
consistent with an emerging body of
evidence challenging the dogma that
exposure to household air pollution is a
major cause of COPD, including a recent
pooled analysis of BOLD study data from
low-, middle-, and high-income countries
(20). This analysis found no association
between spirometric obstruction and self-
reported use of solid fuels for cooking or
heating. This is, however, an area of
controversy, with investigators disagreeing
about the interpretation of the available
data (21, 22).
Many of the studies conducted to date
looking at the association between COPD
and exposure to household air pollution
have had important methodological
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Figure 3. Scatter plot between personal exposure to particulate matter ,2.5 mm in aerodynamic
diameter (PM2.5) and carbon monoxide (CO).
Table 2. Odds Ratios (95% Confidence Interval) for Chronic Respiratory Symptom Outcomes Estimated by Multivariable Logistic
Regression
Variable Cough Phlegm* Wheeze* Dyspnea* Functional Limitation Any Symptoms
Age, yr 1.01 (1.00–1.02) 1.00 (0.97–1.02) 1.02 (0.99–1.05) 1.01 (0.98–1.04) 1.00 (0.95–1.02) 1.00 (0.97–1.02)
Male Ref Ref Ref Ref Ref Ref
Female 0.78 (0.49–1.25) 1.02 (0.42–2.51) 0.97 (0.30–3.28) 3.08 (0.88–11.65) 1.17 (0.28–2.37) 1.08 (0.70–1.67)
Never smoked Ref Ref Ref Ref Ref Ref
Ever smoked 1.56 (1.01–2.41) 1.37 (0.58–3.15) 0.77 (0.20–2.47) 1.85 (0.51–6.07) 0.65 (0.18–1.93) 1.59 (1.05–2.39)
Previous TB: no Ref — — — Ref Ref
Previous TB: yes 2.81 (1.19–6.08) — — — 2.64 (0.40–9.95) 2.50 (1.04–15.58)
Years of
education
0.97 (0.92–1.02) 0.90 (0.81–1.00) 0.99 (0.86–1.13) 0.96 (0.83–1.10) 1.06 (0.96–1.16) 0.98 (0.93–1.03)
Definition of abbreviations: Ref = reference; TB = tuberculosis.
All models were also adjusted for weight (kg) and height (cm); total n = 1,303 owing to missing weight data.
*Only one person had both TB and wheeze, one person had both TB and phlegm, and one person had both TB and dyspnea; TB was excluded from
these models.
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limitations, including case definition and
exposure assessments. So far, studies of the
long-term effects of air pollution have had to
use a self-reported history of exposure with
all the limitations that this may imply. To
improve exposure assessment, we included
48 hours of personal air pollution exposure
measurements in study participants in
addition to questionnaire-based exposure
assessments. Although this approach and
the particular devices used have their
limitations, by doing this we were able to
deliver the first study of the burden of
noncommunicable lung disease anywhere in
the world to incorporate BOLD study
methodology andmeasurements of personal
air pollution exposure and to do so in almost
1,000 participants.
Although personal air pollution
exposure levels were undoubtedly high
and at levels at which adverse health
effects would be expected, and although
widely considered a risk factor for
noncommunicable respiratory diseases and
COPD in particular, the only respiratory
outcome associated with measured exposure
to PM2.5 or CO was “any chronic
respiratory symptoms” with increased
CO exposure. Interestingly, whether
questionnaire-based or directly measured
personal air pollution exposure assessments
were used, there was no significant
association between air pollution exposure
and an increased risk of spirometric
abnormalities. However, we acknowledge
that 48-hour measurements of air
pollutants may not be an adequate
surrogate for cumulative exposure to
household air pollution that has been
associated, albeit by self-report, with
COPD. Our observations, taken together
with the findings of other recent studies,
bring into question the extent to which
household air pollution and other sources
of air pollution play in the development of
abnormal lung function in rural African
settings similar to this one in rural Malawi.
It is plausible that the levels of personal
exposure to air pollution seen are not high
enough to accelerate lung function decline
and the development of airflow obstruction
in the way that tobacco smoke does; a
prospective cohort study of the rate of
decline in lung function in relationship to
air pollution exposures is needed in adults
in sub-Saharan Africa to explore this
further.
This study benefited from being
conducted at the same time and in the
same villages as CAPS, which presented
the opportunity to look for an effect of
the CAPS intervention on respiratory
symptoms, spirometric indices, and
personal air pollution exposures in a
subsample of adults. Consistent with the
main trial findings of no effect of the
intervention on pneumonia in children
,5 years of age (5), we found no evidence
that the intervention was associated with
beneficial effects on any of these trial
secondary outcome measures among
adults. However, these analyses were
exploratory secondary analyses limited by a
relatively small number of participants and
therefore statistical power to detect effects
and, although sufficient to see an effect on
symptoms and air pollution exposures,
there was limited time between intervention
and outcome assessment for potential
effects on spirometric indices to be seen.
Other possible explanations for the lack
Table 3. Coefficient Estimates (95% Confidence Interval) for Continuous Spirometry Outcomes FEV1, FVC, and FEV1/FVC Ratio
(n = 886)
Variable FEV1 FVC FEV1/FVC
Age, yr 20.02 (20.02 to 20.02) 20.01 (20.01 to 20.01) 20.28 (20.31 to 20.24)
Male Ref Ref Ref
Female 20.53 (20.60 to 20.45) 20.70 (20.78 to 20.62) 1.37 (0.18 to 2.56)
Never smoked Ref Ref Ref
Ever smoked 20.09 (20.16 to 20.01) 20.05 (20.14 to 0.04) 21.76 (22.99 to 20.53)
Previous TB: no Ref Ref Ref
Previous TB: yes 20.46 (20.64 to 20.28) 20.36 (20.56 to 20.15) 27.83 (210.74 to 24.91)
Years of education 0 (0 to 0.01) 0 (20.01 to 0.01) 0.18 (0.05 to 0.3)
Definition of abbreviations: Ref = reference; TB = tuberculosis.
All models were also adjusted for weight (kg) and height (cm).
Table 4. Odds Ratios (95% Confidence Interval) for Symptom Outcomes Estimated by Multivariable Logistic Regression in
Participants with Exposure Measurements (n = 985)
Cough Phlegm* Wheeze* Dyspnea* Functional Limitation Any Symptoms
Ever smoked (ref:
never smoked)
1.72 (1.02–2.91) 0.99 (0.37–2.53) 0.35 (0.02–2.32) 2.62 (0.56–11.24) 0.78 (0.20–2.47) 1.67 (1.02–2.71)
Previous TB (ref:
no previous TB)
2.87 (1.07–6.87) — — — 3.00 (0.5–11.74) 2.47 (0.91–6.07)
CO (log10 ppm) 1.29 (0.93–1.77) 1.50 (0.83–2.54) 2.12 (0.96–4.16) 1.27 (0.48–2.88) 1.45 (0.81–2.43) 1.46 (1.04–2.05)
PM2.5 log10 mg/m
3) 1.02 (0.95–1.13) 0.96 (0.88–1.11) 1.00 (0.87–1.38) 1.11 (0.89–1.67) 0.99 (0.90–1.16) 1.02 (0.95–1.11)
Definition of abbreviations: CO = carbon monoxide; PM2.5 = particulate matter ,2.5 mm in aerodynamic diameter; ref = reference; TB = tuberculosis.
All models were adjusted for weight (kg), height (cm), age (yr), sex (male, female), and years of formal education.
*Only one person had both TB and wheeze, one person had both TB and phlegm, and one person had both TB and dyspnea; TB was excluded from
these models.
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of effect of the CAPS intervention on
these outcomes include insufficient levels
of intervention adoption, insufficient
reductions in emissions and exposures, and
other sources of air pollution exposure
overwhelming any potential effect of the
intervention (5).
A notable observation of this study was
that 35% of participants had spirometric
restriction when benchmarked against
NHANES III white reference range values.
We consider the approach we have taken of
benchmarking against the NHANES III
white reference ranges as the best we can do
at this time while accepting that this and all
other currently available alternatives are not
ideal. That includes locally derived reference
ranges that might be helpful in defining
what is ‘usual’ lung function in asymptomatic
nonsmoking Malawian adults but that
may be far from “optimal potential
normal lung function.” Because there is
evidence that the prognostic significance
of spirometric restriction holds irrespective
of racial/ethnic group when benchmarked
in this way (23, 24), the finding of such
a high burden of spirometric restriction
in the rural Malawian population, and
elsewhere in sub-Saharan Africa (25, 26),
is of considerable concern; observational
cohort studies are needed to understand
the clinical characteristics and prognostic
significance of these findings. The
underlying drivers of spirometric restriction
in sub-Saharan African populations are not
yet understood, but we hypothesize that
these are primarily environmental insults
experienced in early life (e.g., malnutrition,
infections and air pollution exposures
before conception, in utero, and during
childhood) such that adulthood is reached
without maximal potential lung function
having been achieved. Cross-sectional
studies of the burden and determinants of
noncommunicable lung disease in
children in sub-Saharan Africa are
needed to explore whether the same
patterns of abnormality are seen in early
life and, if so, studies even earlier in the
life course to identify potential windows
of opportunity to intervene to maximize
lung health.
Strengths of this study include that it
was conducted in a highly challenging
research setting in one of the world’s
poorest rural communities as part of the
CAPS protocol; it is the first of the global
BOLD studies to be conducted in a rural
sub-Saharan African setting; and it is also
the first BOLD study to incorporate
personal air pollution exposure
measurements and to do so at scale.
Limitations include questionnaire
assessments for most variables with
potential for recall bias; the potential bias
(e.g., underestimation of the burden of
spirometric abnormalities) caused by
participants who did not do spirometry,
although the quality of those that did
spirometry was generally high; and air
pollution exposure assessments that
provided only a 48-hour snapshot of
exposure and were based on a light-
scattering method alone for PM2.5.
In conclusion, we found that exposures
to air pollution among Malawian adults
living in communities participating in CAPS
were at levels well beyond those considered
safe by the WHO. In keeping with the
primary outcome of the CAPS trial, we
found no effect of the intervention on any of
Table 5. Coefficient Estimates (95% Confidence Interval) for Continuous Spirometry Outcomes FEV1, FVC, and FEV1/FVC Ratio in
Participants with Personal Air Pollution Exposure Measurements (n = 886)
Variable FEV1 FVC FEV1/FVC
Age, yr 20.02 (20.02 to 20.01) 20.01 (20.02 to 20.01) 20.28 (20.35 to 20.20)
Male Ref Ref Ref
Female 20.58 (20.61 to 20.44) 20.70 (20.79 to 20.60) 1.25 (20.09 to 2.56)
Never smoked Ref Ref Ref
Ever smoked 20.1 (20.19 to 20.02) 20.07 (20.16 to 0.03) 21.83 (23.20 to 20.45)
Previous TB: no Ref Ref Ref
Previous TB: yes 20.32 (20.52 to 20.11) 20.26 (20.49 to 20.02) 26.16 (29.48 to 22.85)
Years of education 0 (0 to 0.01) 0 (20.01 to 0.01) 0.15 (0.01 to 0.29)
CO (log10 ppm) 0.01 (20.04 to 0.06) 0.01 (20.04 to 0.07) 0.13 (20.68 to 0.94)
PM2.5 (log10 mg/m
3) 0 (20.02 to 0.01) 0 (20.01 to 0.01) 20.11 (20.29 to 0.08)
For definition of abbreviations, see Table 4.
All models were also adjusted for weight (kg) and height (cm).
Table 6. CAPS Intention-to-Treat Secondary Trial Analyses (n = 424)
Outcome Intervention (n = 227) Control (n = 197)
Intervention vs. Control
Coefficient Estimate (95% CI) P Value
Symptoms, n (%) 22 (9.7) 26 (13.2) 0.90 (0.45 to 1.82)* 0.87
FEV1, median (IQR) 2.81 (2.39 to 3.26) 2.77 (2.40 to 3.10) 0.08 (20.06 to 0.22) 0.26
FVC, median (IQR) 3.37 (2.88 to 3.91) 3.31 (2.83 to 3.86) 0.04 (20.13 to 0.21) 0.62
Mean CO, median (IQR) 1.13 (0.79 to 1.90) 1.28 (0.82 to 1.79) 0.67 (20.60 to 1.96) 0.30
Mean PM2.5, median (IQR) 67.90 (44.72 to 112.95) 64.47 (40.73 to 101.80) 2931.6 (22,073.6 to 209.7) 0.11
Definition of abbreviations: CAPS = Cooking and Pneumonia Study; CI = confidence interval; CO = carbon monoxide; IQR = interquartile range; PM2.5 =
particulate matter ,2.5 mm in diameter.
Mean exposure per individual is calculated, and the median (IQR) of those values is reported.
*Odds ratio (95% CI).
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the secondary trial outcomes (i.e.,
respiratory symptoms, spirometric indices,
or air pollution exposures) in the
subsample of adults participating in both
this study and the trial. The prevalence
of chronic respiratory symptoms and
abnormal spirometry suggests that
there may be an important burden of
noncommunicable respiratory disease in
these communities. The characteristics
of noncommunicable respiratory disease
in sub-Saharan Africa may be different
to those previously expected, with
more spirometric restriction and less
obstruction (and household air
pollution–associated COPD) than has
been thought to exist. There is a need to
explore other plausible explanations for
the poor lung function observed in these
and other low- and middle-income
country populations, including further
exploration of the role of TB, recurrent
pneumonia, and nutrition. Clinically
effective and cost-effective approaches
for the prevention and control of
noncommunicable respiratory diseases
are very much needed in sub-Saharan
Africa. n
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